2030 Compounding Drug Development 
Drug Patent Watch
DECEMBER 10, 2024
This shift has led to the emergence of integrated contract development and manufacturing organizations (CDMOs), which provide end-to-end support for drug developers. billion in 2022 and is expected to grow at a compound annual growth rate of 5.3% from 2023 to 2030. from 2023 to 2030. References Patheon.
European Pharmaceutical Review
JUNE 28, 2023
million by 2030, growing at a compound annual growth rate (CAGR) of 5.57 percent from 2023 to 2030. Growth of the pharmaceutical and biotechnology industries, plus the need for accurate and precise analytical tools in drug development and quality control are influencing factors. percent between 2023 and 2030.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
AUGUST 17, 2022
According to a recent report , the global formulation development outsourcing market size should grow to $61.4 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide.
European Pharmaceutical Review
JULY 24, 2023
A paper published in Pharmaceutics has proposed how a personalised preparation quality assurance programme can achieve this when these products are developed in compounding laboratories. PACMI selects a drug on a quarterly basis. It requests that compounding laboratories adhering to the programme send samples of it.
pharmaphorum
AUGUST 2, 2022
The potential for ADCs to combine the best of both mAbs and small molecule drugs means that there has been high interest in developing a successful compound since the first successful clinical trial in 1983. At present, there are 12 approved treatments and the development work being done to bring more through is only increasing.
European Pharmaceutical Review
APRIL 3, 2024
Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. As such, the sector is expected to grow at a compounded annual growth rate (CAGR) of 6.5 percent between 2022-2030. percent between 2022-2030.
European Pharmaceutical Review
DECEMBER 21, 2022
Organic compounds are arguably the foundation of the pharmaceutical industry. All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. In the context of CO 2 neutrality, the years 2030 and 2050 are mentioned as crucial milestones.
Expert insights. Personalized for you.
83 
Let's personalize your content